Statera Biopharma Stock Net Income
| STAB Stock | USD 0.0002 0.0001 100.00% |
As of the 8th of February, Statera Biopharma has the Coefficient Of Variation of 466.92, risk adjusted performance of 0.1824, and Semi Deviation of 21.68. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Statera Biopharma, as well as the relationship between them.
Statera Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Statera Biopharma's valuation are provided below:Statera Biopharma does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Statera |
Statera Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Statera Biopharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Statera Biopharma.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Statera Biopharma on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Statera Biopharma or generate 0.0% return on investment in Statera Biopharma over 90 days. Statera Biopharma is related to or competes with HST Global. Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune... More
Statera Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Statera Biopharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Statera Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 66.41 | |||
| Information Ratio | 0.2124 | |||
| Maximum Drawdown | 275.0 | |||
| Value At Risk | (66.67) | |||
| Potential Upside | 100.0 |
Statera Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Statera Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Statera Biopharma's standard deviation. In reality, there are many statistical measures that can use Statera Biopharma historical prices to predict the future Statera Biopharma's volatility.| Risk Adjusted Performance | 0.1824 | |||
| Jensen Alpha | 11.16 | |||
| Total Risk Alpha | 5.9 | |||
| Sortino Ratio | 0.1641 | |||
| Treynor Ratio | (4.69) |
Statera Biopharma February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1824 | |||
| Market Risk Adjusted Performance | (4.68) | |||
| Mean Deviation | 31.52 | |||
| Semi Deviation | 21.68 | |||
| Downside Deviation | 66.41 | |||
| Coefficient Of Variation | 466.92 | |||
| Standard Deviation | 51.29 | |||
| Variance | 2630.68 | |||
| Information Ratio | 0.2124 | |||
| Jensen Alpha | 11.16 | |||
| Total Risk Alpha | 5.9 | |||
| Sortino Ratio | 0.1641 | |||
| Treynor Ratio | (4.69) | |||
| Maximum Drawdown | 275.0 | |||
| Value At Risk | (66.67) | |||
| Potential Upside | 100.0 | |||
| Downside Variance | 4409.72 | |||
| Semi Variance | 469.88 | |||
| Expected Short fall | (115.00) | |||
| Skewness | 1.85 | |||
| Kurtosis | 4.66 |
Statera Biopharma Backtested Returns
Statera Biopharma is out of control given 3 months investment horizon. Statera Biopharma owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.19, which indicates the firm had a 0.19 % return per unit of risk over the last 3 months. We were able to analyze twenty-seven different technical indicators, which can help you to evaluate if expected returns of 9.92% are justified by taking the suggested risk. Use Statera Biopharma Coefficient Of Variation of 466.92, risk adjusted performance of 0.1824, and Semi Deviation of 21.68 to evaluate company specific risk that cannot be diversified away. Statera Biopharma holds a performance score of 15 on a scale of zero to a hundred. The entity has a beta of -2.34, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Statera Biopharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Statera Biopharma is expected to outperform it. Use Statera Biopharma coefficient of variation, maximum drawdown, skewness, as well as the relationship between the total risk alpha and downside variance , to analyze future returns on Statera Biopharma.
Auto-correlation | 0.10 |
Insignificant predictability
Statera Biopharma has insignificant predictability. Overlapping area represents the amount of predictability between Statera Biopharma time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Statera Biopharma price movement. The serial correlation of 0.1 indicates that less than 10.0% of current Statera Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.1 | |
| Spearman Rank Test | 0.17 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Statera Biopharma reported net income of (101.88 Million). This is 129.85% lower than that of the Healthcare sector and 245.44% lower than that of the Biotechnology industry. The net income for all United States stocks is 117.84% higher than that of the company.
Statera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Statera Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Statera Biopharma could also be used in its relative valuation, which is a method of valuing Statera Biopharma by comparing valuation metrics of similar companies.Statera Biopharma is currently under evaluation in net income category among its peers.
Statera Fundamentals
| Return On Equity | -2.87 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (5.73) % | |||
| Current Valuation | 12.92 M | |||
| Shares Outstanding | 54.66 M | |||
| Shares Owned By Insiders | 15.93 % | |||
| Shares Owned By Institutions | 5.41 % | |||
| Number Of Shares Shorted | 1.25 M | |||
| Price To Book | 0.16 X | |||
| Price To Sales | 1.61 X | |||
| Revenue | 1.49 M | |||
| Gross Profit | 998.72 K | |||
| EBITDA | (97.27 M) | |||
| Net Income | (101.88 M) | |||
| Cash And Equivalents | 506.1 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 10.62 M | |||
| Debt To Equity | 0.23 % | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0.20) X | |||
| Cash Flow From Operations | (28.19 M) | |||
| Short Ratio | 0.39 X | |||
| Earnings Per Share | (0.76) X | |||
| Number Of Employees | 46 | |||
| Market Capitalization | 1.97 M | |||
| Total Asset | 21.17 M | |||
| Z Score | -13.2 | |||
| Net Asset | 21.17 M |
About Statera Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Statera Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Statera Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Statera Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Statera Pink Sheet
Statera Biopharma financial ratios help investors to determine whether Statera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Statera with respect to the benefits of owning Statera Biopharma security.